FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Stem Cell Res Ther / In vitro MSC function is related to clinical reaction in viv...
Stem cell research & therapy2018; 9(1); 295; doi: 10.1186/s13287-018-1037-4

In vitro MSC function is related to clinical reaction in vivo.

Abstract: We recently demonstrated that intracellular xenogen-contaminated autologous MSCs (FBS) and non-xenogen-contaminated allogeneic (ALLO) MSCs caused an adverse clinical response after repeated intra-articular injection in horses, whereas autologous (AUTO) MSCs did not. Our current objective was to use clinical data from the previous study to compare MSC stemness against adverse response indicated by synovial total nucleated cell count (TNCC) following intra-articular MSC injection. Stemness, quantified by a trilineage differentiation (TLD) score; immunomodulation, quantified by mixed lymphocyte reactions (MLRs); and degree of MHCI expression, quantified by mean fluorescent intensity (MFI); were correlated to the synovial TNCC 24 h after naïve and primed injection. There was a trend of a negative correlation (p = 0.21, r = - 0.44) between TLD score and TNCC after primed injection in the ALLO group. Within the ALLO group only, there was a significant positive correlation (p = 0.05, r = 0.77) between MHCI MFI and TNCC after naïve injection and a trend (p = 0.16, r = 0.49) of a positive association of MHCI MFI to TNCC after primed injection. Within the FBS group only, there was a positive correlation (p = 0.04, r = 1) between TNCC and lymphocyte proliferation after both injections. The trend of a negative correlation of TLD score and TNCC in the ALLO, but not the FBS group, together with the association of MHCI expression and TNCC in the ALLO group, indicates that improved stemness is associated with reduced MSC immunogenicity. When inflammation was incited by xenogen, there was a strong correlation of lymphocyte activation in vitro to adverse response in vivo, confirming that MLRs in vitro reflect MSC immunomodulatory activity in vivo. The relationship of stemness in vitro, suppression of lymphocyte activation in vitro, MHCI expression in vitro, and clinical response in vivo should be further investigated.
Get Full Text
Publication Date: 2018-11-08 PubMed ID: 30409211PubMed Central: PMC6225557DOI: 10.1186/s13287-018-1037-4Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research looks into the correlation between the functions of Mesenchymal Stem Cells (MSCs) in vitro (in a controlled environment) and their reactions in vivo (inside the body). The study specifically examines the clinical responses seen in horses after repeated intra-articular injections of different types of MSCs and how these reactions relate to measures of MSC ‘stemness’, immunomodulation and MHCI expression in vitro.

Research Objectives and Methodology

  • The main purpose of this study was to understand how the ‘stemness’ (ability to reproduce into various types of cells) of MSCs relates to adverse reactions in horses, measured by the synovial total nucleated cell count (TNCC), after intra-articular injections.
  • The study looked at laboratory (in vitro) measurements of stemness using a Trilineage Differentiation (TLD) score, immunomodulation using the results of Mixed Lineage Reactions (MLRs), and MHCI expression using the mean fluorescent intensity (MFI).
  • The researchers compared these laboratory measurements to clinical outcomes in horses after injecting autologous MSCs (from the same individual), xenogen-contaminated autologous MSCs (MSCs from the same individual but contaminated with materials from a different species), and non-xenogen-contaminated allogeneic MSCs (MSCs from a different individual of the same species).

Research Findings

  • A trend of negative correlation was observed in the ALLO group between the TLD score (stemness) and the TNCC after the primed injection, which suggests that a higher level of stemness could lead to a reduced adverse response.
  • In the ALLO group, there was a significant positive correlation between the MHCI MFI (a measure of an immune response) and the TNCC after the naïve injection. There was also a trend of the same positive correlation after the primed injection.
  • In the FBS group, a positive correlation was observed between TNCC and lymphocyte proliferation after both injections.

Conclusions

  • The results suggest that an improved level of stemness in MSCs could be associated with their lower immunogenicity.
  • Also, when inflammation was caused by xenogen, there was a strong relationship between lymphocyte activation in the lab and the adverse response inside the body. This reaffirms the notion that the in-vitro MLRs mirror the in-vivo immunomodulatory activity of the MSCs.
  • Further research should be carried out to understand the connection between in-vitro stemness, suppression of lymphocyte activation, MHCI expression, and the in-vivo clinical response of the MSCs.

Cite This Article

APA
Rowland AL, Xu JJ, Joswig AJ, Gregory CA, Antczak DF, Cummings KJ, Watts AE. (2018). In vitro MSC function is related to clinical reaction in vivo. Stem Cell Res Ther, 9(1), 295. https://doi.org/10.1186/s13287-018-1037-4

Publication

Stem cell research & therapy
ISSN: 1757-6512
NlmUniqueID: 101527581
Country: England
Language: English
Volume: 9
Issue: 1
Pages: 295
PII: 295

Researcher Affiliations

Rowland, Aileen L
  • Department of Large Animal Clinical Sciences, Texas A&M University, College Station, TX, USA.
Xu, Jiajie Jessica
  • Department of Large Animal Clinical Sciences, Texas A&M University, College Station, TX, USA.
Joswig, Amanda Jo
  • Department of Large Animal Clinical Sciences, Texas A&M University, College Station, TX, USA.
Gregory, Carl A
  • Department of Molecular and Cellular Medicine, Institute for Regenerative Medicine, Texas A&M Health Science Center, College Station, TX, USA.
Antczak, Douglas F
  • Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
Cummings, Kevin J
  • Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY, USA.
Watts, Ashlee E
  • Department of Large Animal Clinical Sciences, Texas A&M University, College Station, TX, USA. awatts@cvm.tamu.edu.

MeSH Terms

  • Animals
  • Cell Differentiation
  • Cell Lineage
  • Cell Proliferation
  • Fluorescence
  • Haplotypes
  • Histocompatibility Antigens Class I / metabolism
  • Horses
  • Lymphocyte Culture Test, Mixed
  • Mesenchymal Stem Cell Transplantation
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / metabolism
  • Time Factors

Conflict of Interest Statement

ETHICS APPROVAL: This study was approved by the university’s Institutional Animal Care and Use Committee (IACUC protocol number 2013-097 and 2015-0038). No animals were euthanized for this study. CONSENT FOR PUBLICATION: Not applicable COMPETING INTERESTS: The authors declare that they have no competing interest. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

This article includes 26 references
  1. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection.. J Inflamm (Lond) 2005 Jul 26;2:8.
    doi: 10.1186/1476-9255-2-8pmc: PMC1215510pubmed: 16045800google scholar: lookup
  2. Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response.. Biol Blood Marrow Transplant 2007 Apr;13(4):412-22.
    doi: 10.1016/j.bbmt.2006.12.447pmc: PMC1892590pubmed: 17382248google scholar: lookup
  3. Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.. Equine Vet J 2017 Jul;49(4):539-544.
    doi: 10.1111/evj.12647pmc: PMC5425313pubmed: 27862236google scholar: lookup
  4. Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.. Stem Cell Res Ther 2015 Apr 12;6(1):54.
    pmc: PMC4414005pubmed: 25889095doi: 10.1186/s13287-015-0053-xgoogle scholar: lookup
  5. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.. Blood 2006 Sep 15;108(6):2114-20.
    doi: 10.1182/blood-2005-11-011650pmc: PMC1895546pubmed: 16690970google scholar: lookup
  6. Oliveira RL, Chagastelles PC, Sesterheim P, Pranke P. In Vivo Immunogenic Response to Allogeneic Mesenchymal Stem Cells and the Role of Preactivated Mesenchymal Stem Cells Cotransplanted with Allogeneic Islets.. Stem Cells Int 2017;2017:9824698.
    pmc: PMC5434460pubmed: 28553360doi: 10.1155/2017/9824698google scholar: lookup
  7. Joswig AJ, Mitchell A, Cummings KJ, Levine GJ, Gregory CA, Smith R 3rd, Watts AE. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model.. Stem Cell Res Ther 2017 Feb 28;8(1):42.
    pmc: PMC5329965pubmed: 28241885doi: 10.1186/s13287-017-0503-8google scholar: lookup
  8. Lysák D, Koutová L, Holubová M, Vlas T, Miklíková M, Jindra P. The Quality Control of Mesenchymal Stromal Cells by in Vitro Testing of Their Immunomodulatory Effect on Allogeneic Lymphocytes.. Folia Biol (Praha) 2016;62(3):120-30.
    pubmed: 27516191
  9. Bertolo A, Gemperli A, Gruber M, Gantenbein B, Baur M, Pötzel T, Stoyanov J. In vitro cell motility as a potential mesenchymal stem cell marker for multipotency.. Stem Cells Transl Med 2015 Jan;4(1):84-90.
    doi: 10.5966/sctm.2014-0156pmc: PMC4275012pubmed: 25473086google scholar: lookup
  10. Russell KC, Phinney DG, Lacey MR, Barrilleaux BL, Meyertholen KE, O'Connor KC. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment.. Stem Cells 2010 Apr;28(4):788-98.
    doi: 10.1002/stem.312pubmed: 20127798google scholar: lookup
  11. Deskins DL, Bastakoty D, Saraswati S, Shinar A, Holt GE, Young PP. Human mesenchymal stromal cells: identifying assays to predict potency for therapeutic selection.. Stem Cells Transl Med 2013 Feb;2(2):151-8.
    doi: 10.5966/sctm.2012-0099pmc: PMC3659751pubmed: 23362238google scholar: lookup
  12. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.. Cytotherapy 2006;8(4):315-7.
    doi: 10.1080/14653240600855905pubmed: 16923606google scholar: lookup
  13. Okolicsanyi RK, Griffiths LR, Haupt LM. Mesenchymal stem cells, neural lineage potential, heparan sulfate proteoglycans and the matrix.. Dev Biol 2014 Apr 1;388(1):1-10.
    doi: 10.1016/j.ydbio.2014.01.024pubmed: 24509075google scholar: lookup
  14. Wong TY, Chang CH, Yu CH, Huang LLH. Hyaluronan keeps mesenchymal stem cells quiescent and maintains the differentiation potential over time.. Aging Cell 2017 Jun;16(3):451-460.
    doi: 10.1111/acel.12567pmc: PMC5418204pubmed: 28474484google scholar: lookup
  15. Grogan SP, Barbero A, Winkelmann V, Rieser F, Fitzsimmons JS, O'Driscoll S, Martin I, Mainil-Varlet P. Visual histological grading system for the evaluation of in vitro-generated neocartilage.. Tissue Eng 2006 Aug;12(8):2141-9.
    doi: 10.1089/ten.2006.12.2141pubmed: 16968155google scholar: lookup
  16. Tseng CT, Miller D, Cassano J, Bailey E, Antczak DF. Identification of equine major histocompatibility complex haplotypes using polymorphic microsatellites.. Anim Genet 2010 Dec;41 Suppl 2(Suppl 2):150-3.
    doi: 10.1111/j.1365-2052.2010.02125.xpmc: PMC3289534pubmed: 21070289google scholar: lookup
  17. Vidal MA, Kilroy GE, Johnson JR, Lopez MJ, Moore RM, Gimble JM. Cell growth characteristics and differentiation frequency of adherent equine bone marrow-derived mesenchymal stromal cells: adipogenic and osteogenic capacity.. Vet Surg 2006 Oct;35(7):601-10.
    pubmed: 17026544doi: 10.1111/j.1532-950X.2006.00197.xgoogle scholar: lookup
  18. Paterson YZ, Rash N, Garvican ER, Paillot R, Guest DJ. Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro.. Stem Cell Res Ther 2014 Jul 30;5(4):90.
    doi: 10.1186/scrt479pmc: PMC4247727pubmed: 25080326google scholar: lookup
  19. Flaminio MJ, Rush BR, Davis EG, Hennessy K, Shuman W, Wilkerson MJ. Characterization of peripheral blood and pulmonary leukocyte function in healthy foals.. Vet Immunol Immunopathol 2000 Mar 15;73(3-4):267-85.
    doi: 10.1016/S0165-2427(00)00149-5pubmed: 10713340google scholar: lookup
  20. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014 Jan 24;5(1):13.
    doi: 10.1186/scrt402pmc: PMC4055004pubmed: 24461709google scholar: lookup
  21. Pogozhykh O, Pogozhykh D, Neehus AL, Hoffmann A, Blasczyk R, Müller T. Molecular and cellular characteristics of human and non-human primate multipotent stromal cells from the amnion and bone marrow during long term culture.. Stem Cell Res Ther 2015 Aug 22;6(1):150.
    pmc: PMC4546288pubmed: 26297012doi: 10.1186/s13287-015-0146-6google scholar: lookup
  22. Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.. Equine Vet J 2017 Jul;49(4):539-544.
    doi: 10.1111/evj.12647pmc: PMC5425313pubmed: 27862236google scholar: lookup
  23. Guest DJ, Ousey JC, Smith MR. Defining the expression of marker genes in equine mesenchymal stromal cells.. Stem Cells Cloning 2008;1:1-9.
    pmc: PMC3781685pubmed: 24198500doi: 10.2147/sccaa.s3824google scholar: lookup
  24. Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F, Murphy M, O'Brien T, Ritter T. Immunogenicity of allogeneic mesenchymal stem cells.. J Cell Mol Med 2012 Sep;16(9):2094-103.
    doi: 10.1111/j.1582-4934.2011.01509.xpmc: PMC3822979pubmed: 22151542google scholar: lookup
  25. Zajonc DM, Girardi E. Recognition of Microbial Glycolipids by Natural Killer T Cells.. Front Immunol 2015;6:400.
    pmc: PMC4523824pubmed: 26300885doi: 10.3389/fimmu.2015.00400google scholar: lookup
  26. Berglund AK, Fisher MB, Cameron KA, Poole EJ, Schnabel LV. Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers.. Front Vet Sci 2017;4:84.
    pmc: PMC5466990pubmed: 28660198doi: 10.3389/fvets.2017.00084google scholar: lookup

Citations

This article has been cited 7 times.
  1. Kahrizi MS, Mousavi E, Khosravi A, Rahnama S, Salehi A, Nasrabadi N, Ebrahimzadeh F, Jamali S. Recent advances in pre-conditioned mesenchymal stem/stromal cell (MSCs) therapy in organ failure; a comprehensive review of preclinical studies.. Stem Cell Res Ther 2023 Jun 7;14(1):155.
    doi: 10.1186/s13287-023-03374-9pubmed: 37287066google scholar: lookup
  2. Cequier A, Vázquez FJ, Romero A, Vitoria A, Bernad E, García-Martínez M, Gascón I, Barrachina L, Rodellar C. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility.. Front Vet Sci 2022;9:957153.
    doi: 10.3389/fvets.2022.957153pubmed: 36337202google scholar: lookup
  3. Cequier A, Romero A, Vázquez FJ, Vitoria A, Bernad E, Fuente S, Zaragoza P, Rodellar C, Barrachina L. Equine Mesenchymal Stem Cells Influence the Proliferative Response of Lymphocytes: Effect of Inflammation, Differentiation and MHC-Compatibility.. Animals (Basel) 2022 Apr 11;12(8).
    doi: 10.3390/ani12080984pubmed: 35454231google scholar: lookup
  4. Rowland AL, Burns ME, Levine GJ, Watts AE. Preparation Technique Affects Recipient Immune Targeting of Autologous Mesenchymal Stem Cells.. Front Vet Sci 2021;8:724041.
    doi: 10.3389/fvets.2021.724041pubmed: 34595230google scholar: lookup
  5. Zhou T, Yuan Z, Weng J, Pei D, Du X, He C, Lai P. Challenges and advances in clinical applications of mesenchymal stromal cells.. J Hematol Oncol 2021 Feb 12;14(1):24.
    doi: 10.1186/s13045-021-01037-xpubmed: 33579329google scholar: lookup
  6. Ramos TD, Silva JD, da Fonseca-Martins AM, da Silveira Pratti JE, Firmino-Cruz L, Maciel-Oliveira D, Dos-Santos JS, Tenorio JIN, de Araujo AF, Freire-de-Lima CG, Diaz BL, Cruz FF, Rocco PRM, de Matos Guedes HL. Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis.. Stem Cell Res Ther 2020 Aug 31;11(1):374.
    doi: 10.1186/s13287-020-01889-zpubmed: 32867857google scholar: lookup
  7. Kamaldinov T, Erndt-Marino J, Levin M, Kaplan DL, Hahn MS. Assessment of Enrichment of Human Mesenchymal Stem Cells Based on Plasma and Mitochondrial Membrane Potentials.. Bioelectricity 2020 Mar 1;2(1):21-32.
    doi: 10.1089/bioe.2019.0024pubmed: 32292894google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.